Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Masataka Hikota is active.

Publication


Featured researches published by Masataka Hikota.


Bioorganic & Medicinal Chemistry Letters | 2014

The discovery of avanafil for the treatment of erectile dysfunction: a novel pyrimidine-5-carboxamide derivative as a potent and highly selective phosphodiesterase 5 inhibitor.

Toshiaki Sakamoto; Yuichi Koga; Masataka Hikota; Kenji Matsuki; Michino Murakami; Kohei Kikkawa; Kotomi Fujishige; Jun Kotera; Kenji Omori; Hiroshi Morimoto; Koichiro Yamada

Novel pyrimidine-5-carboxamide derivatives bearing a 3-chloro-4-methoxybenzylamino group at the 4-position were identified as potent and highly selective phosphodiesterase 5 inhibitors. Among them, we successfully found 10j (avanafil) which exhibited a potent relaxant effect on isolated rabbit cavernosum (EC30=2.1 nM) and a high isozyme selectivity.


Bioorganic & Medicinal Chemistry Letters | 2014

Design and synthesis of novel 5-(3,4,5-trimethoxybenzoyl)-4-aminopyrimidine derivatives as potent and selective phosphodiesterase 5 inhibitors: Scaffold hopping using a pseudo-ring by intramolecular hydrogen bond formation

Toshiaki Sakamoto; Yuichi Koga; Masataka Hikota; Kenji Matsuki; Michino Murakami; Kohei Kikkawa; Kotomi Fujishige; Jun Kotera; Kenji Omori; Hiroshi Morimoto; Koichiro Yamada

5-(3,4,5-Trimethoxybenzoyl)-4-amimopyrimidine derivatives were found as a novel chemical class of potent and highly selective phosphodiesterase 5 inhibitors. A pseudo-ring formed by an intramolecular hydrogen bond constrained the conformation of 3-chloro-4-methoxybenzylamino and 3,4,5-trimethoxybenzoyl substituents and led to the discovery of T-6932 (19a) with a potent PDE5 inhibitory activity (IC50 = 0.13 nM) and a high selectivity over PDE6 (IC50 ratio: PDE6/PDE5 = 2400). Further modification at the 2-position of T-6932 resulted in the finding of 26, which exhibited potent relaxant effects on isolated rabbit corpus cavernosum (EC30 = 11 nM) with a high PDE5 selectivity over PDE6 (IC50 ratio: PDE6/PDE5 = 2800).


Bioorganic & Medicinal Chemistry Letters | 2015

8-(3-Chloro-4-methoxybenzyl)-8H-pyrido[2,3-d]pyrimidin-7-one derivatives as potent and selective phosphodiesterase 5 inhibitors

Toshiaki Sakamoto; Yuichi Koga; Masataka Hikota; Kenji Matsuki; Hideki Mochida; Kohei Kikkawa; Kotomi Fujishige; Jun Kotera; Kenji Omori; Hiroshi Morimoto; Koichiro Yamada

A novel series of highly selective phosphodiesterase 5 (PDE5) inhibitors was found. 8H-Pyrido[2,3-d]pyrimidin-7-one derivatives bearing an (S)-2-(hydroxymethyl)pyrrolidin-1-yl group at the 2-position and a 3-chloro-4-methoxybenzyl group at the 8-position exhibited potent PDE5 inhibitory activities and high PDE5 selectivity over PDE6. Among the synthesized compounds, the 5-methyl analogue (5b) showed the most potent relaxant effect on isolated rabbit corpus cavernosum with an EC30 value of 0.85 nM.


Archive | 2001

Nitrogenous five-membered ring compounds

Kosuke Yasuda; Hiroshi Morimoto; Saburo Kawanami; Masataka Hikota; Takeshi Matsumoto; Kenji Arakawa


Archive | 2001

Aliphatic nitrogenous five-membered ring compounds

Kosuke Yasuda; Hiroshi Morimoto; Saburo Kawanami; Masataka Hikota; Takeshi Matsumoto; Kenji Arakawa


Archive | 2004

Aliphatic nitrogen - containing 5 - membered ring compound

Kosuke Yasuda; Hiroshi Morimoto; Saburo Kawanami; Masataka Hikota; Takeshi Matsumoto; Kenji Arakawa


Archive | 2001

Nitrogenous 5-membered ring compounds

Kosuke Yasuda; Hiroshi Morimoto; Saburo Kawanami; Masataka Hikota; Takeshi Matsumoto; Kenji Arakawa


Archive | 2002

Pyridopyrimidine or naphthyridine derivative

Koichiro Yamada; Masataka Hikota; Yuichi Koga; Kohei Kikkawa; Kenji Omori


Archive | 2006

Nitrogen-containing 5-membered ring compound

Kosuke Yasuda; Hiroshi Morimoto; Saburo Kawanami; Masataka Hikota; Takeshi Matsumoto; Kenji Arakawa


Archive | 2006

Norvaline Derivative and Method for Preparation Thereof

Naoyuki Harada; Masataka Hikota

Collaboration


Dive into the Masataka Hikota's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kenji Arakawa

Mitsubishi Tanabe Pharma

View shared research outputs
Top Co-Authors

Avatar

Kosuke Yasuda

Mitsubishi Tanabe Pharma

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kohei Kikkawa

Mitsubishi Tanabe Pharma

View shared research outputs
Top Co-Authors

Avatar

Yuichi Koga

Mitsubishi Tanabe Pharma

View shared research outputs
Top Co-Authors

Avatar

Jun Kotera

Mitsubishi Tanabe Pharma

View shared research outputs
Researchain Logo
Decentralizing Knowledge